-
Je něco špatně v tomto záznamu ?
Úprava koagulopatie při krvácení do mozku v souvislosti s warfarinem
[Correction of coagulopathy in warfarin associated cerebral hemorrhage]
Venkatesh Aiyagari, Fernando D. Testai
Jazyk čeština Země Česko
Typ dokumentu přehledy
- MeSH
- antikoagulancia farmakologie krev škodlivé účinky MeSH
- aplikace orální MeSH
- faktor VII aplikace a dávkování terapeutické užití MeSH
- farmakoterapie metody MeSH
- hemokoagulace MeSH
- INR MeSH
- intrakraniální krvácení MeSH
- klinické zkoušky jako téma MeSH
- koagulopatie farmakoterapie MeSH
- krevní plazma MeSH
- lidé MeSH
- nenasazení léčby MeSH
- protrombin aplikace a dávkování farmakologie terapeutické užití MeSH
- směrnice pro lékařskou praxi jako téma MeSH
- vitamin K aplikace a dávkování terapeutické užití MeSH
- warfarin farmakologie krev škodlivé účinky MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- přehledy MeSH
Warfarin is the most commonly used oral anticoagulant. Intracranial hemorrhage is the most serious complication of anticoagulation and the anticoagulant effect of warfarin has to be urgently reversed in this situation. Traditional methods of reversal of the anticoagulant effect of warfarin involving the use of vitamin K and fresh frozen plasma are slow and relatively ineffective and there is a need for alternative treatment approaches. RECENT FINDINGS: Agents such as prothrombin complex conjugates and recombinant activated factor VII are being increasingly used to emergently correct warfarin-associated coagulopathy. Over the last decade, several small case series have suggested that these agents may lead to more rapid correction of the INR, however, improved clinical outcome is yet to be proven. A recent small prospective trial has also demonstrated the safety of a prothrombin complex conjugate and its efficacy in rapidly correcting an elevated INR in these patients. SUMMARY: There is a need for well designed randomized clinical trials aimed at evaluating the efficacy of these agents in improving the outcome of patients with anticoagulant associated intracranial hemorrhage.
Correction of coagulopathy in warfarin associated cerebral hemorrhage
Lit.: 45
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07526443
- 003
- CZ-PrNML
- 005
- 20111210143031.0
- 008
- 090724s2009 xr e cze||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a cze $b eng
- 044 __
- $a xr
- 100 1_
- $a Aiyagari, Venkatesh $7 gn_A_00002755
- 245 10
- $a Úprava koagulopatie při krvácení do mozku v souvislosti s warfarinem / $c Venkatesh Aiyagari, Fernando D. Testai
- 246 11
- $a Correction of coagulopathy in warfarin associated cerebral hemorrhage
- 314 __
- $a Department of Neurology and Rehabilitation, University of Illinois at Chicago, Chicago aiyagari@uic.edu
- 504 __
- $a Lit.: 45
- 520 9_
- $a Warfarin is the most commonly used oral anticoagulant. Intracranial hemorrhage is the most serious complication of anticoagulation and the anticoagulant effect of warfarin has to be urgently reversed in this situation. Traditional methods of reversal of the anticoagulant effect of warfarin involving the use of vitamin K and fresh frozen plasma are slow and relatively ineffective and there is a need for alternative treatment approaches. RECENT FINDINGS: Agents such as prothrombin complex conjugates and recombinant activated factor VII are being increasingly used to emergently correct warfarin-associated coagulopathy. Over the last decade, several small case series have suggested that these agents may lead to more rapid correction of the INR, however, improved clinical outcome is yet to be proven. A recent small prospective trial has also demonstrated the safety of a prothrombin complex conjugate and its efficacy in rapidly correcting an elevated INR in these patients. SUMMARY: There is a need for well designed randomized clinical trials aimed at evaluating the efficacy of these agents in improving the outcome of patients with anticoagulant associated intracranial hemorrhage.
- 650 _2
- $a koagulopatie $x farmakoterapie $7 D001778
- 650 _2
- $a warfarin $x farmakologie $x krev $x škodlivé účinky $7 D014859
- 650 _2
- $a aplikace orální $7 D000284
- 650 _2
- $a intrakraniální krvácení $7 D020300
- 650 _2
- $a antikoagulancia $x farmakologie $x krev $x škodlivé účinky $7 D000925
- 650 _2
- $a vitamin K $x aplikace a dávkování $x terapeutické užití $7 D014812
- 650 _2
- $a nenasazení léčby $7 D028761
- 650 _2
- $a farmakoterapie $x metody $7 D004358
- 650 _2
- $a krevní plazma $7 D010949
- 650 _2
- $a protrombin $x aplikace a dávkování $x farmakologie $x terapeutické užití $7 D011516
- 650 _2
- $a faktor VII $x aplikace a dávkování $x terapeutické užití $7 D005167
- 650 _2
- $a INR $7 D019934
- 650 _2
- $a hemokoagulace $7 D001777
- 650 _2
- $a klinické zkoušky jako téma $7 D002986
- 650 _2
- $a směrnice pro lékařskou praxi jako téma $7 D017410
- 650 _2
- $a lidé $7 D006801
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Testai, Fernando D.
- 773 0_
- $w MED00156011 $t Current opinion in critical care $g Roč. 3, č. 2 (2009), s. 25-30 $x 1802-3819
- 910 __
- $a ABA008 $b B 2484 $c 422 $y 9
- 990 __
- $a 20090724112807 $b ABA008
- 991 __
- $a 20090811092001 $b ABA008
- 999 __
- $a ok $b bmc $g 668817 $s 526077
- BAS __
- $a 3
- BMC __
- $a 2009 $b 3 $c 2 $d 25-30 $i 1802-3819 $m Current Opinion in Critical Care (České vyd.) $x MED00156011
- LZP __
- $a 2009-25/mkrk